Matricelf (MTLF.TA) Hisse Fiyat

Matricelf Ltd. is a biotechnology company, which engages in research and development of a platform for autologous matrix and cell implants in the field of regenerative medicine and tissue engineering. The firm operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The firm focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.